Simon Delmotte 
Glioblastoma is one of the most common and severe brain cancers. It affects more than 25,000 patients per year in Europe and the United States.The technology developed by Hemerion for the treatment of this pathology, which is the result of more than 10 years of research by INSERM, the Lille University Hospital and the University …
Already awarded the Galien MedStartup prize, the innovation trophy of the Hauts-de-France region and winner of the Bpifrance i-Lab competition, Hemerion Therapeutics won on March 15, 2023 the “Coup de coeur du Public” prize at the 2nd edition of the Healthtech 2023 Trophies organized by France Biotech, in the presence of Mr. Roland Lescure, the …
Maximilien Vermandel and Prof. Nicolas Reyns are organizing a demonstration of the Hemerion technology associated with the surgical treatment of glioblastoma during the 2023 Congress of the French Society of Neurosurgery. Organized on March 15 at 4:00 pm in Lille Grand Palais, the demonstration will detail the mechanism of action and the functioning of the …
Professor Costas Hadjipanayis, a member of Hemerion’s Scientific Advisory Board, has been appointed head of several neurosurgery centers at the University of Pittsburgh in the USA. An active member of the Hemerion Scientific Board, Prof. Hadjipanayis is a pioneer in several neurosurgery technologies: stereotactic radiosurgery, awake surgery, interstitial laser thermotherapy (TTIL), fluorescence-guided surgery (FGS) and …
Two years after its launch, Hemerion Therapeutics inaugurated its new premises on Thursday, October 20. Located in Villeneuve d’Ascq in the North of France, Hemerion Headquarters houses the team in charge of the clinical development of its brain cancer therapy, as well as industrial prototyping and R&D facilities. Launched in 2020 on the basis of …
A new mission organized by Hemerion in the United States enabled us to test the new version of the Heliance laser diffuser and to specify the outlines of the phase 2 trial in the treatment of glioblastoma. After a first mission in April 2022 in Boston, the Hemerion team continues its clinical development in the …
Five years ago, on May, 12th 2017, Pr. Nicolas Reyns delivered, for the first time ever, the therapy currently being developed by Hemerion. It was the first time that this approach was evaluated, in a frontline setup, for a patient harboring newly diagnosed glioblastoma (GBM). The technology proposed for the treatment of GBM was based …
One year after the first round of funding, Hemerion’s new €3.55 million financing will accelerate the implementation of international clinical trials for the treatment of glioblastoma, the most aggressive brain cancer. Hemerion Therapeutics has already initiated its clinical program with a successful first study in glioblastoma patients. Ultimately, the therapeutic solutions developed by Hemerion could …
Presentation of the Hemerion technology, meeting with investors, neurosurgeons and care centers, discussions about North American regulations: Hemerion has set new milestones for its international development during a 5-day mission in Boston. With more than 13,000 new cases of glioblastoma (GBM) diagnosed each year, the United States is, along with Europe, one of the most …
Newsweek released its annual World’s Best Hospitals 2022 on Wednesday, March 2. The 2022 edition ranks Hemerion’s clinical contributors in the TOP 100 healthcare centers: an international recognition of the quality of their care and the clinical excellence of their medical teams. An international ranking based on clinical excellence Launched in 2019, Newsweek’s “World’s Best …